Targeted antimicrobials are described and related, compositions, methods and systems.

Methods for diagnosis or prognosis of a cancer in a subject are provided and include the steps of: obtaining a biological sample from a subject; determining an amount of a phosphorylation at a Y260 residue in a Na/K ATPase present in the biological sample; and comparing the amount of the phosphorylation in the sample to a control level to thereby diagnose the cancer. Methods for detecting a metabolic switch from oxidative phosphorylation to aerobic glycolysis are also provided in which a biological sample including one or more cells is obtained and an amount of a phosphorylation at a Y260 residue in a Na/K ATPase is determined in the one or more cells.

A method is useful for diagnosing AIG, which includes the step of detecting whether autoantibodies against the beta-subunit of the gastric H.sup.+/K.sup.+-ATPase are present or not in a sample comprising antibodies. The method utilizes a diagnostically useful carrier that contains a solid phase on which an agent for the specific capture of the autoantibody is immobilized. Furthermore, the diagnostically useful carrier includes a solid phase on which an agent for the specific capture of an autoantibody against the beta-subunit of the gastric H.sup.+/K.sup.+-ATPase is immobilized.

The present invention relates to the discovery that delivery of EGFR to cell surface requires EGFR-SAR1A binding. Thus, the invention provides a method for identifying inhibitors of EGFR-SAR1A binding, which can serve as therapeutic agents for treating conditions involving undesirable EGFR signaling. The invention also provides novel composition and its use that suppresses the specific binding between EGFR and SAR1A for the purpose of treating or preventing a condition involving undesired EGFR signaling.

The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

The present invention discloses an assay device (1) for detecting active enzyme in a sample. Said assay device (1) comprises the following components: (a) a placement region (10) onto which the sample can be placed; (b) a matrix (20) operably connected to said placement region (10) such that the sample when present (such as placed) on said placement region (10) can migrate along said matrix (20); (c) at least one distinct capture location (30) on said matrix (20), wherein each distinct capture location (30) is distanced away from the placement region (10), and wherein the sample can migrate across said distinct capture location (30); (d) capture means (40) being present at or defining each distinct capture location (30), wherein said capture means (40) are capable of binding to said enzyme such that at least a portion of said sample of said enzyme is retained at at least one distinct capture location (30); and (e) selective indication means (50), or at least a component thereof, to provide selective indication of the presence of active enzyme bound to said capture means (40).

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.

This invention belongs to the field of biotechnology, in particular to a mutant double-strand DNA (dsDNA) helicase protein nanopore derived from bovine papillomavirus and its application. The technical problem to be solved by this invention is to overcome the deficiency that the existing small-diameter protein nanopore requires an external strength or component to transport dsDNA. The technical scheme in this invention to solve the above deficiency is to provide a truncated E1-1 (306-577) protein, an E1-2 (306-605) protein and its variant derived from bovine papillomavirus double-stranded DNA helicase protein, as well as a variant of its homologous protein which is used for preparing membrane containing conductive channel, providing a new and effective choice for this field.

A method for treating cancer in a human subject includes initiating a cancer therapy on the human subject, preparing a biological sample from the human subject; (i) mixing the biological sample with an antibody or aptamer that specifically binds to an MEST protein, or (ii) obtaining mRNA of a nucleotide sequence encoding the MEST protein from the biological sample, and synthesizing and amplifying cDNA from the mRNA, detecting the MEST protein bound to the antibody or aptamer, or an expression of the cDNA, determining if the detected MEST or a level of the expression is higher than that in a normal human subject, determining responsiveness of the cancer to the cancer therapy by the detected MEST or the level of the expression, and continuing the cancer therapy to treat the cancer if it is determined that there is the responsiveness of the cancer to the cancer therapy.